- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00465426
HIV and Cardiovascular Risk
October 30, 2012 updated by: Steven K. Grinspoon, MD, Massachusetts General Hospital
Assessment of Cardiovascular Risk in HIV Patients
HIV-infected patients treated with combination antiretroviral therapy demonstrate metabolic abnormalities that may predispose them to cardiovascular disease.
In HIV-infected patients we will investigate progression rates of cardiovascular disease and assess whether these progression rates are predicted by increased inflammatory indices.
Study Overview
Status
Completed
Conditions
Detailed Description
HIV-infected patients treated with combination antiretroviral (ARV) therapy increasingly demonstrate metabolic abnormalities, including dyslipidemia, insulin resistance and body composition abnormalities that may predispose them to cardiovascular disease (CVD).
Initial studies suggest increased carotid intima-media thickness (IMT) and endothelial dysfunction in this population.
Increased carotid IMT over time has been demonstrated in HIV-infected patients compared to control subjects.
However, traditional risk factors, such as dyslipidemia, diabetes mellitus and body composition changes alone do not fully predict increased cardiovascular disease in HIV-infected patients.
One possible explanation is increased inflammation, related directly to effects of ARV therapy or indirectly from changes in fat distribution.
In preliminary studies, our group has shown that changes in fat distribution were highly predictive of TNF and IL-6, as well as adiponectin, and that specific inflammatory cytokines were related in cross-sectional studies to increased IMT.
In the proposed study we will investigate using detailed methodologies the relationship between adipocytokine concentrations and subclinical atherosclerosis in both cross-sectional and longitudinal studies.
We will determine in HIV-infected patients on ARVs for greater than 6 months, progression rates of IMT and whether progression rates are predicted by increased inflammatory indices, controlling for traditional risk factors, and body composition changes.
We will test the hypothesis that inflammation, more than traditional risk factors and ARV use, mediates subclinical atherosclerotic disease in HIV-infected patients.
Study Type
Observational
Enrollment (Actual)
129
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Massachusetts General Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Probability Sample
Study Population
Flyers and advertisements regarding this study will be posted in community centers and newspapers
Description
Inclusion Criteria:
Inclusion Criteria for Group 1 (HIV-infected group)
- Age greater than or equal to 18 and less than or equal to 65 years of age
- HIV positive, on the same combination ARV regimen for > than 6 months, including but not limited to either 2 NRTIs and an NNRTI or PI, or a triple NRTI regimen
- CD4 >350 cells/mm3
Inclusion Criteria for Group 2 (HIV Negative, Healthy Control, age and BMI matched to HIV subjects)
- No history of HIV infection (negative HIV test)
- Age greater than or equal to 18 and less than or equal to 65 years of age
Exclusion Criteria:
Exclusion Criteria for Group 1 (HIV-infected group)
- Hgb < 10.0 g/dL, creatinine > 1.5 mg/dL, SGPT > 2.5x ULN
- Use of glucocorticoid, testosterone, growth hormone or other anabolic agents within the past 6 months
- New antiretroviral regimen within 6 months of study initiation
- Active substance abuse
- Medications known to affect glucose or body composition
- Positive pregnancy test or recently pregnant within the past year or lactating
- Presence of active cancers
- Acute viral, bacterial or other infections (excluding HIV)
- Weight loss in the past 3 months of greater than 10 pounds
Criteria for Group 2 (HIV Negative, Healthy Control, age and BMI matched to HIV subjects)
- Hgb < 10.0 g/dL, creatinine > 1.5 mg/dL, SGPT > 2.5x ULN
- Use of glucocorticoid, testosterone, growth hormone or other anabolic agents within the past 6 months.
- Active substance abuse
- Medications known to affect glucose or body composition
- Positive pregnancy test or recently pregnant within the past year or lactating
- Acute viral, bacterial or other infections
- Weight loss in the past 3 months of greater than 10 pounds
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Case-Control
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
---|
1
HIV Positive men and women 18-65 years of age
|
2
HIV negative men and women 18-65 years of age
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Blood pressure
Time Frame: 2 years
|
2 years
|
Carotid Intima Media Thickness
Time Frame: 2 years
|
2 years
|
Waist Circumference
Time Frame: 2 years
|
2 years
|
Lipid levels
Time Frame: 2 years
|
2 years
|
Glucose
Time Frame: 2 years
|
2 years
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Inflammatory markers
Time Frame: 2 years
|
2 years
|
Visceral adiposity
Time Frame: 2 years
|
2 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Steven K Grinspoon, MD, Massachusetts General Hospital
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
April 1, 2007
Primary Completion (Actual)
November 1, 2011
Study Completion (Actual)
November 1, 2011
Study Registration Dates
First Submitted
April 24, 2007
First Submitted That Met QC Criteria
April 24, 2007
First Posted (Estimate)
April 25, 2007
Study Record Updates
Last Update Posted (Estimate)
October 31, 2012
Last Update Submitted That Met QC Criteria
October 30, 2012
Last Verified
October 1, 2012
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- DK49302-10AR
- R01DK049302 (U.S. NIH Grant/Contract)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV Infections
-
University of MinnesotaWithdrawnHIV Infections | HIV/AIDS | Hiv | AIDS | Aids/Hiv Problem | AIDS and InfectionsUnited States
-
University of California, San DiegoUniversity of California, Los Angeles; University of Southern California; California... and other collaboratorsCompleted
-
National Institute of Allergy and Infectious Diseases...Eunice Kennedy Shriver National Institute of Child Health and Human Development...CompletedHIV Infections | HIV SeronegativityUnited States, Puerto Rico
-
Erasmus Medical CenterCompletedHIV/AIDS | Opportunistic Infections, HIV RelatedNetherlands
-
Gérond'ifRecruiting
-
University of California, DavisCompleted
-
University of California, San DiegoNational Center for Complementary and Integrative Health (NCCIH)CompletedHIV PositiveUnited States
-
University of ChicagoUniversity of Athens; National Development and Research Institutes, Inc.Completed
-
HIV Prevention Trials NetworkNational Institute on Drug Abuse (NIDA); National Institute of Allergy and...CompletedHIV PositiveIndonesia, Ukraine, Vietnam
-
University of ZimbabweCompleted